Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2017 10,4 M
EBIT 2017 -17,3 M
Net income 2017 -17,1 M
Finance 2017 0,75 M
Yield 2017 -
Sales 2018 24,0 M
EBIT 2018 7,00 M
Net income 2018 5,00 M
Finance 2018 6,00 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 22,00
EV / Sales2017 11,9x
EV / Sales2018 4,92x
Capitalization 124 M
More Financials
Company
Onxeo SA is a biotechnology company, which engages in the development of drugs for the treatment of orphan diseases.It produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq and AsiDNA.The company was founded by Gilles Avenard and Dominique Costantini on... 
Sector
Pharmaceuticals
Calendar
08/03Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
04/26 ONXEO : Annual General Meeting of April 26, 2017
04/26 ONXEO : Q1 2017 Financial Information and Business Update
04/25 ONXEO : Publication of 2016 Registration Document
04/25 ONXEO : Announces Publication of 2016 Reference Document
04/24 Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe..
04/24 Onxeo Announces Publication of 2016 Reference Document
04/24 ONXEO : Clinigen and Onxeo initiate Managed Access programme for belinostat in E..
04/05 ONXEO : Combined General Meeting on April 26, 2017
03/07 ONXEO : Full-year 2016 Results and Outlook for 2017
03/02ONXEO SA : annual earnings release
More news
Sector news : Pharmaceuticals - NEC
02:37pDJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
10:30a REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
07:45aDJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
04/27DJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue -- Update
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 8,10 €
Spread / Average Target 207%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Judith Greciet Chief Executive Officer & Director
Joseph S. Zakrzewski Non-Executive Chairman
Nicolas Fellmann Chief Financial Officer & Secretary
Françoise Bono Chief Scientific Officer
Olivier de Beaumont Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOALLIANCE PHARMA SA135
JOHNSON & JOHNSON7.40%335 446
ROCHE HOLDING LTD.10.83%225 921
NOVARTIS AG2.77%203 449
PFIZER INC.4.25%201 641
MERCK & CO., INC.6.30%171 565
More Results